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Endogenous pyrogen (EP), ~ the protein which mediates fever, is normally 
synthesized and released by polymorphonuclear (PMN) and mononuclear (MN) 
phagocytes after stimulation by inflammatory agents such as endotoxin or by 
the phagocytosis of bacteria (1). Normal leukocytes contain no detectable pyro- 
gen,  and do  not produce any during in  vitro incubation.  After stimulation, 
however, pyrogen production begins within a  few hours and continues at  a 
steady rate for 12 or more hours (2-4). New protein synthesis is required for the 
initiation of pyrogen production by both PMN and MN leukocytes, but only MN 
leukocytes require continuing protein synthesis in order for pyrogen production 
and release to proceed (4). The mechanisms by which inflammatory agents 
initiate production of EP, and the processes by which cells secrete this small 
protein, are entirely unknown. 
Colchicine, an anti-inflammatory agent, inhibits many PMN leukocyte func- 
tions, including chemotaxis (5, 6), adhesiveness (7), locomotion (8), degranula- 
tion (9, 10), phagocytosis (11), and metabolic responses to particle ingestion (9, 
11). It also inhibits pinocytosis and induction of lysosomal enzymes in cultured 
mouse macrophages (12). In other cell systems, colchicine inhibits secretion of 
various cellular products, including insulin (13), thyroid hormone (14), growth 
hormone and prolactin (15), plasma proteins (16), and catecholamines (17) and 
histamine  (18). All these effects of colchicine have usually been ascribed to 
altered function of microtubular proteins, cell constituents to which colchicine 
binds selectively (19). 
Since fever, due to EP production, commonly follows  an inflammatory re- 
sponse, and since colchicine inhibits secretion of many other cellular products, 
the effect of this drug and related compounds on EP production and release by 
leukocytes was investigated. Contrary to expectation, the results of these stud- 
ies indicate that colchicine not only does not suppress pyrogen production by 
stimulated human PMN leukocytes, but, in the absence of other inflammatory 
agents, micromolar concentrations of this compound stimulate EP production 
and release. 
* This work was supported by grants from the U. S. Public Health Service (5RO1-A1-01564-18 
and CA-14655-02). 
Abbreviations  used in thispaper: EP, endogenous pyrogen; MN, mononuclear; PMN, polymor- 
phonuclear. 
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Materials and Methods 
All materials, glassware, and reagents used in these studies were made sterile and pyrogen 
free, usually by heating at 160°C for 2 h  or autoclaving for 90 min. Heat-labile compounds were 
filtered through a  Millipore filter (Swinnex-25; Millipore Corporation, Bedford, Mass.). 
Preparation and Incubation  of Leukocytes.  Human  blood  leukocytes  were  prepared  from 
heparinized venous blood by dextran sedimentation as described previously (2). Incubations were 
carried out in modified Krebs-Ringer  phosphate buffer, pH 7.4, containing 15% homologous serum, 
10 U heparin, 1.5 mg glucose, 50 U penicillin, and 50 #g streptomycin/ml. Leukocyte concentra- 
tions were usually 107/ml, consisting of about 70% granulocytes and 3-5% monocytes. Identical 
methods were used to prepare rabbit blood leukocytes from heparinized blood obtained by cardiac 
puncture. Flasks were shaken for 2-3 h on a  Dubnoff shaking incubator at 37°C, then incubated 
overnight in a stationary incubator. Human blood mononuclear cells were prepared from heparin- 
ized venous blood by flotation over Ficoll-Hypaque as described previously (4). These cells were 
suspended in  Eagle's minimum essential medium  (MEM:  Auto-POW, Flow Laboratories, Inc., 
Rockville, Md.), and incubated overnight in a 5% CO..,-air incubator in Falcon tissue-culture flasks 
(Falcon  Plastics,  Div.  of BioQuest,  Oxnard,  Calif.).  Differential  counts  ranged  from  20-30% 
monocytes, 0-3% PMN leukocytes, and the remainder, small lymphocytes. Since lymphocytes do 
not produce pyrogen (3), these ceils were usually not removed during the incubations. 
In  experiments where  pyrogen  production  by  whole  blood  leukocytes  and  monocytes  was 
compared, some monocytes were exposed to dextran and then washed before incubation, to ensure 
that the different methods of preparation were not responsible for differences in cell function. 
PMN  leukocytes which  have  been  centrifuged through  Ficoll-Hypaque and  then  washed are 
incapable of pyrogen release, however, so such cells could not be studied. 
Pyrogen Assay.  Flask contents were centrifuged at 2,000g for 30 min, cultured in thioglycol- 
late broth to confirm sterility, and assayed for endogenous pyrogen by injection into rabbits as 
described previously (20). Usually supernate from 2 ×  10; PMN leukocytes and 4 ×  10  '' monocytes 
was employed as an assay dose per rabbit. In all experiments, both negative and positive control 
flasks  of leukocytes  were  included,  consisting of cells incubated  in  medium  alone  (negative 
control), and cells stimulated to release pyrogen, usually by addition of heat-killed staphylococci 
(positive control). Supernates from all flasks in each experiment were assayed for pyrogen in the 
same group of rabbits, with few exceptions. Rare experiments in which injection of supernates 
from either control flask produced inappropriate responses were discarded. Cell-associated pyro- 
gen was assayed from supernates of leukocytes disrupted by freeze-thawing as described previ- 
ously (2), except that the wash of the cell button was omitted. 
Reagents.  The  following reagents  were  used:  Colchicine,  sterile  ampule  for  intravenous 
injection, 0.5 mg/ml (Eli Lilly & Co., Indianapolis, Ind.); vinblastine sulfate (Velban) (Eli Lilly & 
Co.), sterile ampule for injection; puromycin dihydrochloride (ICN Nutritional Biochemicals Div., 
International Chemical & Nuclear Corp., Cleveland, Ohio), prepared as described previously (2); 
and lumicolchicine, 2.4 mg/ml solution in alcohol, kindly supplied by Dr. Leslie Wilson, Depart- 
ment of Pharmacology, Stanford Medical Center, Stanford, Calif.; N-desacetyl-N-methylcolchi- 
cine (Colcemid) (Ciba Corp., Summit, N.J.), dissolved in sterile water at 0.5 mg/ml, filtered, and 
diluted further as needed in normal saline. All materials were stored at 4°C or -20°C. Reagents 
were tested for pyrogenicity (endotoxin contamination) before use by dilution with Krebs-Ringer 
phosphate buffer and 10% normal rabbit serum, incubation at 37°C for 30 min, and injection into 
rabbits. Doses at least five times those used for incubations with cells were tested. Heat-killed 
Staphylococcus albus was prepared as described previously (2); 10-30 bacteria per leukocyte were 
used to stimulate pyrogen release. Endotoxin was supernatant typhoid vaccine, prepared as de- 
scribed previously (4). 
Results 
In initial  experiments, human blood leukocytes were incubated with or with- 
out colchicine (10-:'  M) for 1 h, heat-killed  staphylococci were then added, and 
the amount of  pyrogen produced was assayed after  18 h of  incubation. Pretreat- 
ment with colchicine  did  not  affect  the  amount of  EP released by  cells  stimulated PHYLLIS  BODEL  1017 
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FIG.  1.  Peak temperature elevations in rabbits after injection ofsupernates from human 
blood leukocytes incubated for  18 h  with varying concentrations of colchicine.  Supernate 
from 3  x  10  7 human leukocytes was given to each rabbit.  Responses to supernate from 
cells incubated without colcbicine (control} are shown on the far right. In this figure and in 
subsequent ones, each point represents an individual rabbit response; averages are indi- 
cated by the height of the bars. The results of five experiments are demonstrated. 
by phagocytosis.  In these experiments,  as  expected, control leukocytes incu- 
bated without colchicine or staphylococci released no pyrogen. However, cells 
incubated with colchicine alone produced as much pyrogen as cells stimulated 
by phagocytosis. This unexpected finding was confirmed in a  series of further 
experiments (see Fig.  1).  Colchicine consistently induced pyrogen release from 
human blood cells when added  at concentrations greater than  10 -7  M,  and a 
dose-response effect was observed. Proof that the pyrogen-inducing activity of 
colchicine was not due to contaminating endotoxin was obtained by experiments 
with rabbit blood leukocytes (described below). 
Since the results of these studies indicated that concentrations of colchicine 
below 10  -7 M did not stimulate significant EP production, further attempts were 
made to inhibit pyrogen release after phagocytosis, using very low concentra- 
tions of colchicine. Human blood leukocytes were incubated for 1 h with colchi- 
cine at 5 or 2.5  x  10  ~ M,  staphylococci were added, and pyrogen release was 
assayed. There was again no difference between the amount of EP released by 
colchicine-treated, compared to normal, cells stimulated by phagocytosis. 
In  order to determine whether other compounds  which  alter  microtubular 
function would also stimulate pyrogen production in vitro, human blood leuko- 
cytes  were  incubated  with  Colcemid  and  vinblastine.  The  results  of these 
experiments are shown in Fig. 2. Like colchicine, both Colcemid and vinblastine 
induced human blood cells to release pyrogen. On the other hand,  lumicolchi- 
cine,  a  light-altered derivative of colchicine which has  very little affinity for 
microtubules (21),  did not stimulate pyrogen release even when added at  100 
times the concentration at which colchicine is effective. 
Since stimulated blood monocytes produce large quantities of EP (4, 22, 23), it 
was of interest to determine whether mononuclear leukocytes from blood would 1018  COLCHICINE  STIMULATION  OF  PYROGEN  PRODUCTION 
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FIG.  2.  Peak temperature elevations in rabbits after injection of supernates from human 
blood leukocytes incubated for 18 h  without stimulus (control), or with Colcemid (2.5 x  10-:' 
M), vinblastine (4.5 or 9 x  10-:' M), lumicolchicine (2 x  10-:' M), or heat-killed staphylococci. 
also release pyrogen during incubation with colchicine. Preparations of human 
blood monocytes were therefore incubated with several different concentrations 
of colchicine, and pyrogen release was measured. The results of these experi- 
ments, shown in Fig.  3,  indicate that monocytes release pyrogen when incu- 
bated with colchicine at concentrations above 2.5  x  10  -8  M.  A  dose-response 
relationship was observed,  similar to that shown in Fig.  1 for human blood 
(predominantly PMN) leukocytes. The higher average temperature responses 
recorded with supernates from monocytes (Fig. 3) are due to incomplete adjust- 
ment of the assay for the greater yield of pyrogen from monocytes compared to 
that of PMN leukocytes (4,  23). 
In order to exclude the possibility that the pyrogenic activity of colchicine was 
due to contamination of the preparations by small amounts of endotoxin, rabbit 
leukocytes suspended in a  rabbit serum-buffer medium were incubated with 
varying amounts of the drug, and EP release was assayed. Although as little as 
0.001  ~g of endotoxin will induce EP production under such conditions (24), 
colchicine  did  not  induce  pyrogen production  by  rabbit  leukocytes, even  at 
concentrations  as  high  as  10 -4  M  (see  Fig.  4).  The  viability and  pyrogen- 
producing capacity of the rabbit cells were confirmed by addition of staphylo- 
cocci to other flasks, either in the presence or absence of colchicine (right-hand 
bar, Fig. 4).  Similar experiments using both large and minimally stimulating 
doses  of endotoxin,  with  and  without colchicine,  also  failed to  demonstrate 
either stimulatory or inhibitory activity of this agent on rabbit leukocytes. 
Experiments were  next performed to  examine some  characteristics of the 
process by which colchicine or Colcemid induces production and release of EP by 
human leukocytes. In initial experiments, varying concentrations of Colcemid 
were added to human blood monocytes, and the pyrogen released by these cells 
was compared to that released by whole-blood leukocytes. As shown in Fig. 5, at 
low concentrations of Colcemid (2.5 or 5.0 x  10 -~ M), 2 blood leukocytes, predomi- 
nantly granulocytes, produced significant amounts of pyrogen, whereas mono- 
With a  subsequent preparation  of Colcemid, 2.5  x  10 -~ M  was the critical concentration. PHYLLIS  BODEL  1019 
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Fro.  3.  Peak temperature elevations in rabbits after injection of supernates from human 
blood monocytes incubated for 18 h with varying concentrations of colchicine. Responses to 
supernate from cells incubated without colchicine (control) are shown on the far right. 
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FIG. 4.  Peak temperature elevations in rabbits after injection of supernates from 3-6 x  10  ~ 
rabbit blood  leukocytes incubated  for  18  h  with  varying concentrations  of colchicine. 
Responses to supernates from cells incubated with staphylococci and colchicine, or with 
staphylococci alone, are shown on the far right. 
cytes produced  much  less.  At  higher  concentrations  of Colcemid  (not  shown), 
both cell preparations  were stimulated  equally. Since no methods are presently 
available  to  obtain  pure  preparations  of blood  PMN  leukocytes  suitable  for 
studies of pyrogen production, this differential sensitivity of the two cell types to 
low concentrations of Colcemid provided an opportunity to study the mechanism 
of PMN  leukocyte activation by this agent. 
First, human  blood leukocytes were incubated  with Colcemid for 1/2 or 2  h, 
the cells were washed  once in buffer, then resuspended  in fresh media  without 1020  COLCHICINE  STIMULATION  OF PYROGEN  PRODUCTION 
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Fro.  5.  Peak temperature elevations in rabbits after injection of supernates from human 
blood (predominantly PMN) leukocytes, or from preparations of human blood mononuclear 
cells, incubated for 18 h with Colcemid. Supernate from about 2 x  10  7 PMN leukocytes or 4 
x  10" monocytes was given to each rabbit. 
the drug. Other cells were incubated with Colcemid for 18 h as usual. As shown 
in Table I, a  short contact with medium containing Colcemid was sufficient to 
induce nearly normal pyrogen release during the subsequent 16-18 h of incuba- 
tion. These results are similar to those previously observed when staphylococci 
or endotoxin were used as stimuli (3). 
Next, to examine the time-course of EP production in this system, the pyrogen 
content of the  medium was  assayed at different times after the beginning of 
leukocyte  incubation  with  Colcemid  (see  Table  II).  Whereas  pyrogen  from 
leukocytes stimulated by phagocytosis is normally detectable in the medium 3 or 
4 h  after addition of bacteria (2, 3),  pyrogen did not appear in the medium in 
these experiments until  7 or 8 h  after the beginning of incubation with Col- 
cemid. Assays for cell-associated pyrogen were also negative during these 7-8 h 
(not shown), but became positive when pyrogen appeared in the medium. 
Finally,  the  effect of puromycin,  an  inhibitor of protein synthesis,  on the 
process of EP release was examined. Previous studies (2, 25) have shown that 
puromycin prevents production and release of pyrogen from PMN  leukocytes 
only if added  within  1-2  h  after a  phagocytic stimulus.  After this  interval, 
although pyrogen production and release are just beginning, inhibitors of new 
RNA  or protein synthesis  do  not  alter the  process.  To determine  whether a 
similar sequence of events occurs during  induction of pyrogen production by 
Colcemid, puromycin (10-:' M) was added to preparations of leukocytes 2, 4, 6, or 
8 h after Colcemid treatment. Incubations were continued for a total of 18 h, and 
pyrogen release, as well as cell-associated pyrogen content, was then assayed. 
The results, shown in Table III, indicate that when puromycin was added 2 or 4 
h  after Colcemid, subsequent release of EP into the medium was  completely 
prevented. Cell-associated pyrogen also did not develop (not shown), indicating 
that pyrogen production, as well as its release, is inhibited.  When puromycin PHYLLIS  BODEL 
TABLE  I 
Effect of Time of Exposure to Colcemid on Leukocyte Pyrogen Production 
Incubation with  hT (°C) -+ SEM* 
Colcemid (2.5 x 
1021 
10 -6 M)  0 min  30 min  2 h  18 h 
Pyrogen in  18-h  0.07  ±  0.03  (8)$  0.58  -+ 0.04 (6)  0.52  -+ 0.11  (9)  0.74  -+ 0.05 (10) 
supernate 
* Average maximum  temperature elevations in rabbits after injection of supernates *- standard 
errors of the mean. 
$ Number of responses in parentheses. 
TABLE II 
Effect of Time of Incubation  with Colcemid on Pyrogen Production 
AT {°C)  *- SEM* 
Time of incubation with 
colcemid (2.5  x  10 -" M) 
4 h  6-8 h  18 h 
Pyrogen in supernate  0.10 -+ 0.03 (6)$  0.27 ± 0.07 (13)  0.70 -+ 0.09 (9) 
* Average maximum  temperature elevations in rabbits after injection of supernates _+  standard 
errors of the mean. 
Number of responses in parentheses. 
was added 6-8 h  after Colcemid, however, nearly normal pyrogen production 
occurred (see Table III). These results, then, indicate that a brief incubation of 
PMN  leukocytes with  Colcemid  is  sufficient to  induce  EP  production,  that 
leukocytes stimulated by Colcemid do not produce or release pyrogen for many 
hours, and that inhibition of protein synthesis during these hours will prevent 
subsequent EP production. 
Discussion 
When this investigation was begun, it was anticipated that colchicine might 
inhibit pyrogen release from human leukocytes stimulated by phagocytosis, but 
no such effect was observed, even when concentrations of colchicine below 0.1 
#M were used. In contrast, the results of the studies presented here indicate 
that  colchicine,  and  the  related  compound  Colcemid,  activate  human blood 
leukocytes to  produce  and  release  endogenous pyrogen.  This  effect  is  dose 
related, occurring with concentrations of colchicine above 0.1  /~M. Both PMN 
leukocytes and monocytes are stimulated to release pyrogen when incubated 
with these agents. Although contamination of colchicine and Colcemid solutions 
with endotoxin would result in similar activation of leukocytes, this possibility 
is effectively ruled out by the failure of these compounds to activate rabbit blood 
leukocytes.  Rabbit  leukocytes produce  pyrogen when  exposed  to  very small 
amounts  of endotoxin  (24), yet  they failed  to  become  activated by  100  txM 
colchicine, a dose 400 times that required to stimulate human leukocytes. 
Previous studies have shown that colchicine either inhibits, or has no effect 
on,  various functions of leukocytes (5-12).  Similarly, most investigators have 
reported inhibitory effects of colchicine on secretion of cellular products, such as 
hormones and amines (13-18).  In a few instances, however, stimulatory actions 1022  COLCHICINE  STIMULATION  OF  PYROGEN  PRODUCTION 
TABLE  III 
Effect of Puromycin on Pyrogen Production by Leukocytes Incubated with Colcemid* 
Time puromycin  .IT (°C)  .+  SEM~ 
(10-:' M) added 
after incubation  2 h  4 h  6-8 h  None 
begun 
Pyrogen in 18-h  0.10  .+  0.03  (11)§  0.07  .+  0.07  (6)  0.63  _+  0.07  (6)  0.81  +_  0.06 (13) 
supernate 
"2,5  x  10 -~ M 
~; Average maximum  temperature elevations in rabbits after injection of supernates  -+ standard 
errors of the mean. 
§ Number of responses in parentheses. 
of colchicine on the secretory processes of cells have been observed. Explants of 
synovial tissue exposed to colchicine exhibit increased synthesis and release of 
collagenase  (26) and  neutral  protease  (27), as  well  as  prostaglandins  (28). 
Colchicine also markedly stimulates steroid secretion by adrenal tumor cells in 
culture (29). In a recent abstract, colchicine was reported to stimulate secretion 
ofelastase and collagenase by cultured mouse macrophages (30). Concentrations 
of the drug which were effective in these experiments ranged from 0.01 to 1 t~M, 
levels comparable to those used to stimulate pyrogen release from leukocytes in 
the studies reported here. 
Both inhibitory and stimulatory effects of colchicine have usually been as- 
cribed to an action on microtubules, protein constituents of many cells, includ- 
ing leukocytes, to which colchicine binds selectively (19). Colcemid and vinblas- 
tine,  like  colchicine,  interfere  with  the  assembly  of microtubules,  whereas 
lumicolchicine, a light-altered derivative of colchicine, has almost no affinity for 
these structures {21). Since Colcemid and vinblastine, but not lumicolchicine, 
stimulated EP production by normal leukocytes, altered function of microtu- 
bules may in some way lead to EP production and release. 
The failure of colchicine or Colcemid to induce pyrogen production by rabbit 
leukocytes is unexplained. However, different responses of rabbit and human 
leukocytes to  both  pyrogenic  and  antipyrogenic stimuli have  been  reported 
before, in studies with etiocholanolone, hydrocortisone, and estrogen (31). Col- 
chicine  in  a  concentration  of 10 -4  M  does  not  inhibit  chemotaxis of rabbit 
leukocytes (32), whereas much lower concentrations inhibit chemotaxis of hu- 
man leukocytes (5, 6). Rabbit and human leukocytes also differ in morphology 
and contain different proteins and enzymes (33, 34). 
The process of EP production by human blood PMN leukocytes, stimulated by 
phagocytosis or endotoxin, has been studied previously (2, 25). After a stimulus 
is added to normal cells, EP production begins within 2-3  h  and continues for 
about 12 h. During an interval of 1-2 h between addition of the activator and the 
first release of  pyrogen, addition of inhibitors of new RNA and protein synthesis 
prevents subsequent production and release of pyrogen. If added later, however, 
these inhibitors, as well as 10 -~ M sodium fluoride, have no effect. Investigation 
of the mechanism of action of Colcemid in the present studies indicated that 
although the time required for contact between activator and cell is brief, EP PHYLLIS  BODEL  1023 
production and release do not begin for about 6 h. If puromycin is added during 
this time  interval,  but not afterward,  subsequent EP production  is inhibited. 
This  finding suggests that  Colcemid induces  EP production  and  release by a 
process  similar  to  that  of other  activators  studied,  although  the  prolonged 
induction phase distinguishes it from all agents investigated previously except 
etiocholanolone (35). This pyrogenic steroid, however, may activate only mono- 
cytes, not granulocytes, whereas Colcemid, in the concentration used, probably 
activated mainly granulocytes. This conclusion is supported by the observation 
that puromycin did not suppress late release of pyrogen by Colcemid (see Table 
II), whereas late synthesis and release of EP by blood monocytes are inhibited by 
puromycin (4). 
The results of the experiments reported here raise the possibility that disas- 
sembly of microtubules and the resulting disorganization  of cellular structures 
which  occurs when  colchicine  or vinblastine  is  incubated  with  leukocytes in 
vitro  (36-38)  somehow initiate  or stimulate  pyrogen production  and  release. 
Although microtubules could also be involved in the initiation of EP production 
by inflammatory stimuli such as endotoxin or phagocytosis, evidence for such a 
mechanism  is lacking.  Alternatively,  colchicine may act by a  mechanism  not 
involving microtubules- perhaps by altering the structure or function of mem- 
branes,  as  has  been  suggested  previously  (16,  39).  The  fact  that  colchicine 
stimulates  secretion  of certain  cellular  products  while  it  inhibits  release  of 
others,  may provide information  about different pathways for stimulation  and 
secretion of various cellular products. Further studies of the action of colchicine 
on mouse macrophages (12, 30), cells which synthesize and secrete pyrogen (40) 
as well as other protein enzymes (41-43), may be especially helpful in examining 
these relationships. 
Finally, since colchicine has not been reported to be pyrogenic in patients, it is 
unlikely that the in vitro effects seen here are related to its therapeutic actions. 
Concentrations of 0.1 tzM, the minimum level for stimulation of pyrogen produc- 
tion in vitro, are about 10 times higher than those achieved in serum after a full 
therapeutic dose of the drug (44,  45).  When concentrations of 0.05 or 0.025  tzM 
were tested for inhibitory  activity on pyrogen release from leukocytes stimu- 
lated by phagocytosis, no effect was observed. It is improbable, therefore, that 
the antipyretic effects of colchicine seen clinically, as, for example, in familial 
Mediterranean fever (46), are directly due to inhibition of pyrogen production by 
leukocytes. More likely, its anti-inflammatory properties, such as effects on the 
adhesiveness and chemotaxis of neutrophils,  prevent the initial stimulation of 
the cells, which in turn prevents subsequent pyrogen release. 
Summary 
The effect of colchicine, an anti-inflammatory  agent, on endogenous pyrogen 
(EP) production by human blood leukocytes in vitro was examined.  Colchicine 
not only failed to suppress EP production by human  leukocytes stimulated by 
phagocytosis, but, in the absence of other stimuli,  micromolar concentrations of 
the drug  induced pyrogen production  and  release by both polymorphonuclear 
(PMN) and mononuclear leukocytes. The response was dose related,  occurring 
at concentrations above 0.1  #M. Colcemid and vinblastine,  other agents which 1024  COLCHICINE STIMULATION OF  PYROGEN PRODUCTION 
bind to microtubular protein,  also induced pyrogen release from human leuko- 
cytes,  whereas  lumicolchicine,  a  light-altered derivative of colchicine without 
affinity for microtubules, was ineffective. Colchicine did not induce EP produc- 
tion by rabbit leukocytes, even at 100 ~M concentration. Studies of the mecha- 
nism of PMN leukocyte activation by Colcemid indicated that although the time 
required for contact between drug and leukocyte was brief, pyrogen production 
and  release  did  not  begin  for  6  or  more  hours.  If added  during  this  time, 
puromycin  prevented  subsequent  production  and  release  of pyrogen.  These 
results indicate that agents which interfere with the assembly of microtubules 
induce EP production and secretion by human leukocytes in vitro. 
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